TW201444847A - 作爲鉀離子通道抑制劑之吡咯并三嗪 - Google Patents

作爲鉀離子通道抑制劑之吡咯并三嗪 Download PDF

Info

Publication number
TW201444847A
TW201444847A TW103108204A TW103108204A TW201444847A TW 201444847 A TW201444847 A TW 201444847A TW 103108204 A TW103108204 A TW 103108204A TW 103108204 A TW103108204 A TW 103108204A TW 201444847 A TW201444847 A TW 201444847A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
cycloalkyl
phenyl
substituted
Prior art date
Application number
TW103108204A
Other languages
English (en)
Chinese (zh)
Inventor
海瑟 芬雷
艾索 庫瑪 艾迪森漢
卡維塔 葛文卓裘盧
普拉珊沙 古納卡
約翰 洛伊德
波瑟肯努瑞 斯林瓦舒
Original Assignee
必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 必治妥美雅史谷比公司 filed Critical 必治妥美雅史谷比公司
Publication of TW201444847A publication Critical patent/TW201444847A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW103108204A 2013-03-11 2014-03-10 作爲鉀離子通道抑制劑之吡咯并三嗪 TW201444847A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775731P 2013-03-11 2013-03-11
US14/200,055 US9050345B2 (en) 2013-03-11 2014-03-07 Pyrrolotriazines as potassium ion channel inhibitors

Publications (1)

Publication Number Publication Date
TW201444847A true TW201444847A (zh) 2014-12-01

Family

ID=51488539

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103108204A TW201444847A (zh) 2013-03-11 2014-03-10 作爲鉀離子通道抑制劑之吡咯并三嗪

Country Status (8)

Country Link
US (1) US9050345B2 (enExample)
EP (1) EP2970296B1 (enExample)
JP (1) JP6427551B2 (enExample)
CN (1) CN105008367B (enExample)
AR (1) AR095208A1 (enExample)
TW (1) TW201444847A (enExample)
UY (1) UY35381A (enExample)
WO (1) WO2014143610A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013274619B2 (en) * 2012-06-11 2017-09-28 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide
EP2970294B1 (en) 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
WO2014143607A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2018528951A (ja) * 2015-08-31 2018-10-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＴＧＦβ受容体アンタゴニスト
CN105111154A (zh) * 2015-09-15 2015-12-02 上海瑞博化学有限公司 一种5-氨基吡嗪-2-甲酸合成新工艺
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
CA3021185C (en) 2016-04-28 2024-06-04 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
KR20230106648A (ko) * 2020-11-10 2023-07-13 포그혼 쎄라퓨틱스 인크. 화합물 및 그의 용도
EP4504341A1 (en) 2022-04-08 2025-02-12 Shy Therapeutics LLC Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20250024923A (ko) 2022-05-11 2025-02-20 포그혼 쎄라퓨틱스 인크. 화합물 및 그의 용도
EP4610260A4 (en) * 2022-10-28 2025-11-26 Shanghai Shenshi Wise Tech Co Ltd Aryl heterocyclic kv1.3 inhibitor, preparation method therefor, and use thereof
CN116063183B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种环丙胺的合成方法
CN121941688A (zh) * 2023-10-09 2026-04-28 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途
WO2026019945A1 (en) * 2024-07-17 2026-01-22 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2026025999A1 (zh) * 2024-08-01 2026-02-05 浙江海正药业股份有限公司 6,7-二氢-5H-吡咯并[1,2-a]咪唑类衍生物及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT1094816E (pt) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
CZ303660B6 (cs) * 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
KR100847605B1 (ko) 2000-11-17 2008-07-21 브리스톨-마이어스스퀴브컴파니 ｐ38 키나제 관련 질병의 치료 방법 및 키나제 억제제로서유용한 피롤로트리아진 화합물
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004013145A1 (en) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MXPA05008183A (es) 2003-02-05 2005-10-05 Bristol Myers Squibb Co Proceso para preparar pirrolotriazina como inhibidores de cinasa.
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
AP2007003923A0 (en) 2004-09-30 2007-02-28 Tibotec Pharm Ltd Hcv inhibiting bi-cyclic pyrimidines
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
CA2645031A1 (en) 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
CN101511835B (zh) * 2006-07-07 2013-11-27 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2400604T3 (es) 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
CN102015719A (zh) 2008-03-06 2011-04-13 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US20110269740A1 (en) 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
EP2344504B1 (en) * 2008-10-08 2014-06-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
ES2900504T3 (es) 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
AU2013274619B2 (en) * 2012-06-11 2017-09-28 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Also Published As

Publication number Publication date
US20140256719A1 (en) 2014-09-11
JP6427551B2 (ja) 2018-11-21
US9050345B2 (en) 2015-06-09
EP2970296B1 (en) 2016-12-21
WO2014143610A1 (en) 2014-09-18
AR095208A1 (es) 2015-09-30
EP2970296A1 (en) 2016-01-20
JP2016512505A (ja) 2016-04-28
CN105008367B (zh) 2017-08-29
CN105008367A (zh) 2015-10-28
UY35381A (es) 2014-09-30

Similar Documents

Publication Publication Date Title
CN105008367B (zh) 作为钾离子通道抑制剂的吡咯并三嗪类化合物
TWI744218B (zh) 吲哚甲醯胺化合物
JP7307734B2 (ja) キナーゼ阻害剤としてのアミノピロロトリアジン
JP7228586B2 (ja) キナーゼ阻害剤としてのアミノイミダゾピリダジン
JP2020507582A (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
CN112165938A (zh) 因子xiia抑制剂
CN119487018A (zh) 作为irak 4的配体导向降解剂的杂芳基化合物
TW201414737A (zh) 作爲激酶抑制劑之咪唑并三□甲腈
CN105492433B (zh) 6-(5-羟基-1h-吡唑-1-基)烟碱酰胺衍生物和其作为phd抑制剂的用途
TW201713653A (zh) 吡啶並［３，４－ｄ］嘧啶衍生物及其藥學上可被許可的鹽
KR102906523B1 (ko) 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
KR20170075756A (ko) 카르바졸 유도체
JP6386527B2 (ja) カリウムイオンチャネル阻害剤としてのピロロピリダジン
CN114014844A (zh) 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途
JP2016514129A (ja) カリウムイオンチャネル阻害剤としてのフタラジン
TW202334140A (zh) 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法
JP2016516691A (ja) カリウムイオンチャネル阻害剤としてのイソキノリン
IL303320A (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
JP6395798B2 (ja) カリウムイオンチャネル阻害剤としてのピロロトリアジン
WO2025170939A1 (en) Proteasome inhibitors for the treatment of malaria
HK40127584A (zh) Pcsk9抑制剂及其使用方法
TW201514162A (zh) 作爲鉀離子通道抑制劑之呔
NZ754113B2 (en) Indole carboxamide compounds useful as kinase inhibitors
NZ731946B2 (en) Indole carboxamide compounds useful as kinase inhibitors
TW201524980A (zh) 吡唑并吡咯啶衍生物及其治療疾病之用途